Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET – – Findings from the STARS...
United States Michael Shetzline Ironwood Pharmaceuticals Nasdaq Exchange Commission A National Survey Analysis Ironwood Pharmaceuticals
Source: marketscreener.com